• Medicare Advantage (Part C) and Prescription Drug (Part D) programs including: quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs). Medicaid: Advocated on Medicaid redeterminations; presumptive eligibility; and auto-enrollment. Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee; Advocated in support of allowing Medicaid Managed Care Organizations to assist enrollees during redeterminations Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment. Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans. Telehealth: Advocated in support of permanent extension of telehealth flexibilities beyond December 31, 2024 (CONNECT for Health Act, S. 2016/H.R. 4189; the Telehealth Modernization Act, S. 3967/7623); Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act, S. 2061/H.R. 4058). Provider Directories: Advocated on ensuring accuracy of provider directories.
• Advocated on prescription drugs costs, including advocating for the transparency of PBMs and support for the Fair Accountability and Innovative Research (FAIR) Act; Advocated for patent reform and educated on utilization of GLP-1s drugs. Mental and Behavioral Health: advocated in support of integration, collaborative care and access to mental and behavioral health services; advocated greater access to mental and behavioral health services overall; advocated for greater access to tele-mental health services; advocated on mental health parity. Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instance of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans.

Duration: January 1, 2008 to present

General Issues: Medicare/Medicaid, Health Issues, Taxation/Internal Revenue Code, Government Issues, Insurance

Spending: about $24,030,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2008: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Substance Abuse & Mental Health Services Administration (SAMHSA), Centers For Medicare and Medicaid Services (CMS),, Health & Human Services - Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Treasury - Dept of, Natl Economic Council (NEC), Justice - Dept of (DOJ), Internal Revenue Service (IRS), Internal Revenue Service (IRS),